Edition:
United States

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.16EUR
5:49am EST
Change (% chg)

€0.17 (+17.17%)
Prev Close
€0.99
Open
€0.99
Day's High
€1.18
Day's Low
€0.99
Volume
1,655,330
Avg. Vol
469,523
52-wk High
€5.46
52-wk Low
€0.98

Chart for

About

Onxeo SA, formerly Bioalliance Pharma SA, is a France-based biopharmaceutical company. In July 2014, the Company, as the continuing entity, merged with Topotarget AS creating Onxeo, a company dedicated to orphan oncology diseases. Onxeo aims at holding a portfolio of advanced programs targeting severe pathologies with unmet... (more)

Overall

Beta: 0.69
Market Cap(Mil.): €50.18
Shares Outstanding(Mil.): 50.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.96 15.25
EPS (TTM): -- -- --
ROI: -- 15.07 33.27
ROE: -- 16.58 16.35

BRIEF-Onxeo reports commercial court of Paris decision in lawsuit against SpeBio/SpePharm​

* ‍Onxeo reports first instance decision from commercial court of Paris in lawsuit against SpeBio/SpePharm​

Oct 17 2017

BRIEF-Onxeo introduces chemistry platform of decoy oligonucleotides platON

* ONXEO INTRODUCES PLATON™, A PROPRIETARY CHEMISTRY PLATFORM OF DECOY OLIGONUCLEOTIDES

Oct 02 2017

BRIEF-Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​

* ‍ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR ITS TWO INNOVATIVE COMPOUNDS, ASIDNA™ AND BELINOSTAT​

Sep 28 2017

BRIEF-Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics

* ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR THERAPEUTICS

Sep 13 2017

BRIEF-Onxeo divests two non-core products to Vectans Pharma

* ONXEO DIVESTS TWO NON-CORE PRODUCTS IN ORAL PATHOLOGIES TO VECTANS PHARMA

Jul 31 2017

BRIEF-Onxeo H1 net loss stable at 11.6‍​ million euros

* H1 REVENUE EUR ‍​3.4 MILLION VERSUS EUR 1.9 MILLION YEAR AGO

Jul 28 2017

BRIEF-Onxeo announces positive preclinical proof of concept results for AsiDNA

* ONXEO ANNOUNCES POSITIVE PRECLINICAL PROOF OF CONCEPT RESULTS CONFIRMING ASIDNA ACTIVITY VIA SYSTEMIC ADMINISTRATION

Jul 05 2017

BRIEF-Onxeo launches capital increase by means of accelerated book-build offering

* ONXEO LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOK-BUILD OFFERING

Jun 19 2017

Earnings vs. Estimates